Immunohistochemical study of p21(WAF1) and p53 proteins in prostatic cancer and their prognostic significance

Human Pathology

Volumn 29, Issue 8, 1998, Pages 778-783

  Matsushima, Hisashi ^a   Sasaki, Takeshi ^a   Goto, Toshitaka ^a   Hosaka, Yoshio ^a   Homma, Yukio ^a   Kitamura, Tadaichi ^a   Kawabe, Kazuki ^a   Sakamoto, Atsuhiko ^a   Murakami, Toshikazu ^a   Machinami, Rikuo ^a  

^a NONE

Author keywords

Immunohistochemistry; p21(WAF1); p53; Prognosis; Prostate neoplasms

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ANALYSIS; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; ADENOCARCINOMA; ENZYME IMMUNOASSAY; IMAGE PROCESSING; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13144294005     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90445-2     Document Type: Article

References (25)

1. Bookstein R, MacGrogan D, Hilsenbeck SG, et al: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373, 1993
2. Effert PJ, Neubauer A, Walther PJ, et al: Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. J Urol 147:789-793, 1992
3. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993
4. Visakorpi T, Kallioniemi O-P, Heikkinen A, et al: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992
5. Kallakury BV, Figge J, Ross JS, et al: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. HUM PATHOL 25:92-97, 1994
6. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
7. Kennedy SM, Macgeogh C, Jaffe R, et al: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. HUMAN PATHOL 25:438-442, 1994
8. Moll UM, LaQuaglia M, BenardJ, et al: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411, 1995
9. Peng HQ, Hogg D, Malkin D, et al: Mutations of the p53 gene do not occur in testis cancer, Cancer Res 53:3574-3578, 1993
10. MacGeoch C, Barnes DM, Newton JA, et al: p53 protein detected by immunohistochemical staining is not always mutant. Disease Markers 11:239-250, 1993
11. Humphrey PA, Swanson PE: Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. Pathol Res Pract 191:881-887, 1995
12. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
13. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994
14. Parker SB, Eichele G, Zhang P, et al: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027, 1995
15. Gleason D: Histologic grading and clinical staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febriger, 1977, pp 171-198
16. Shi S, Key M, Ralra K: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
17. Bacus SS, Chin DM, Stern RK, et al: HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer. Anal Quant Cytol Histol 14:433-445, 1992
18. Cox DR: Regression models and life-tables. J R Stat Soc series B 34:187-220, 1972
19. WAF1/CIP1/SDI1 gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. HUM PATHOL 27:1211-1220, 1996
20. waf1/cip1/sdi1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. HUM PATHOL 27:912-916, 1996
21. DiGiuseppe JA, Redston MS, Yeo CJ, et al: p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147:884-888, 1995
22. Zhang W, Grasso L, McClain CD, et al: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668-674, 1995
23. Marchetti A, Doglioni C, Barbareschi M, et al: p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12:1319-1324, 1996
24. Barbareschi M, Caffo O, Doglioni C, et al: p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74:208-215, 1996
25. Gao X, Chen YQ, Wu N, et al: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398, 1995